Mahnaz Mirimoghaddam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahnaz Mirimoghaddam has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aida Iraji
Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Fatemeh Moraffah
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Hamid Akbari Javar
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Mahnaz Khanavi
Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Mina Saeedi
Medicinal Plants Research Center Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
1 shared publication - Mohammad-Reza Delnavazi
Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 9 August 2026
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 21 (3) , e171846
Boswellia sacra Flueck. Oleo-gum-resin Nanophytosome: Development, Standardization, and Cholinesterase Inhibitory Potential
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cholinergic dysfunction. The limited efficacy of current acetylcholinesterase inhibitors underscores the need for novel therapeutic approaches. Objectives: This study evaluated the acetylcholinesterase inhibitory activity of Boswellia sacra extracts and their phytosomal formulations. Methods: The methanolic extract of B. sacra was fractionated using potassium hydroxide (KOH) and ethyl acetate to obtain a boswellic acid-enriched fraction, which was further purified by silica gel chromatography to yield two derivatives identified by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy. A phytosomal formulation was prepared using soy lecithin and cholesterol via high-shear homogenization followed by ultrasonication. The optimized nanophytosome was characterized by dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Entrapment efficiency, stability, the in vivo release profile, cholinesterase inhibitory activity was assessed using Ellman’s method. Results: Phytochemical analysis yielded 3-acetyl-11-keto-boswellic acid (1) and 11-keto-boswellic acid (2), and compound 1 was used for standardization. The optimized phytosome exhibited a mean particle size of 112 ± 12.28 nm, a polydispersity index (PDI) of 0.23 ± 0.1, a zeta potential of -53 ± 5.87 mV, and an entrapment efficiency of 75.3 ± 1.47%. FTIR and DSC confirmed molecular interactions between lecithin and the extract, whereas TEM and SEM revealed spherical morphology. The optimized phytosomal formulation demonstrated a gradual release profile, reaching 92% after 12 hours, and increased acetylcholinesterase inhibition to 61.0 ± 10.7% (half-maximal inhibitory concentration [IC50], 177.9 ± 26.8 µg/mL) compared with the non-formulated extract. It also showed moderate butyrylcholinesterase inhibition (42 - 48%) and selectivity for acetylcholinesterase inhibition. Conclusions: The optimized phytosomal formulation enhanced in vitro acetylcholinesterase inhibitory activity compared with the non-formulated extract, indicating the potential of this delivery system to improve the biological activity of Boswellia constituents in cell-free enzyme assays. However, these findings are preliminary and limited to in vitro experiments. Further studies are required to assess blood–brain barrier permeability, neuronal uptake, pharmacokinetics, and in vivo therapeutic efficacy.
- 9 August 2026
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 21 (3) , e171846
Open AccessBoswellia sacra Flueck. Oleo-gum-resin Nanophytosome: Development, Standardization, and Cholinesterase Inhibitory Potential
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cholinergic dysfunction. The limited efficacy of current acetylcholinesterase inhibitors underscores the need for novel therapeutic approaches. Objectives: This study evaluated the acetylcholinesterase inhibitory activity of Boswellia sacra extracts and their phytosomal formulations. Methods: The methanolic extract of B. sacra was fractionated using potassium hydroxide (KOH) and ethyl acetate to obtain a boswellic acid-enriched fraction, which was further purified by silica gel chromatography to yield two derivatives identified by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy. A phytosomal formulation was prepared using soy lecithin and cholesterol via high-shear homogenization followed by ultrasonication. The optimized nanophytosome was characterized by dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Entrapment efficiency, stability, the in vivo release profile, cholinesterase inhibitory activity was assessed using Ellman’s method. Results: Phytochemical analysis yielded 3-acetyl-11-keto-boswellic acid (1) and 11-keto-boswellic acid (2), and compound 1 was used for standardization. The optimized phytosome exhibited a mean particle size of 112 ± 12.28 nm, a polydispersity index (PDI) of 0.23 ± 0.1, a zeta potential of -53 ± 5.87 mV, and an entrapment efficiency of 75.3 ± 1.47%. FTIR and DSC confirmed molecular interactions between lecithin and the extract, whereas TEM and SEM revealed spherical morphology. The optimized phytosomal formulation demonstrated a gradual release profile, reaching 92% after 12 hours, and increased acetylcholinesterase inhibition to 61.0 ± 10.7% (half-maximal inhibitory concentration [IC50], 177.9 ± 26.8 µg/mL) compared with the non-formulated extract. It also showed moderate butyrylcholinesterase inhibition (42 - 48%) and selectivity for acetylcholinesterase inhibition. Conclusions: The optimized phytosomal formulation enhanced in vitro acetylcholinesterase inhibitory activity compared with the non-formulated extract, indicating the potential of this delivery system to improve the biological activity of Boswellia constituents in cell-free enzyme assays. However, these findings are preliminary and limited to in vitro experiments. Further studies are required to assess blood–brain barrier permeability, neuronal uptake, pharmacokinetics, and in vivo therapeutic efficacy.